Galapagos (GLPG) Receives a Hold from Stifel Nicolaus

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Galapagos (GLPG). The company’s shares closed last Wednesday at $92.55.

According to, Archila is a 5-star analyst with an average return of 17.1% and a 53.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Phasebio Pharmaceuticals, and Alexion Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Galapagos with a $123.87 average price target.

See today’s analyst top recommended stocks >>

Galapagos’ market cap is currently $7.15B and has a P/E ratio of -16.10. The company has a Price to Book ratio of 2.20.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts